AEVI 002

Drug Profile

AEVI 002

Alternative Names: Anti-LIGHT monoclonal antibody; MDGN-002; Research programme: anti-LIGHT monoclonal antibody - sanofi-aventis; SAR 252067

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator Kyowa Hakko Kirin; La Jolla Institute for Allergy & Immunology
  • Developer Aevi Genomic Medicine; Kyowa Hakko Kirin; Sanofi; The Childrens Hospital of Philadelphia
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor ligand superfamily member 14 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Crohn's disease
  • Discontinued Ulcerative colitis

Most Recent Events

  • 02 Jun 2017 Aevi Genomic Medicine plans a phase I trial for Crohn's Disease in USA (SC) (NCT03169894)
  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
  • 01 Jul 2016 Phase-I/II clinical trials in Crohn's disease (In adolescents, In infants, In children, In neonates) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top